Preface_2023_Neuroimaging-in-Parkinson--s-Disease-and-Related-Disorders

Prévia do material em texto

Preface
Neuroimaging techniques play a pivotal
role in the research and clinical landscape of
Parkinson’s and related disorders by helping
to understand biological signatures of the
disease, to aid the diagnosis, disease moni-
toring, and pursuit for new therapeutic
targets and novel drug development. The
past 20 years has seen a rapid evolution of
technological advances that has led to
prompt developments in brain imaging
techniques such as with magnetic resonance
imaging (MRI), position emission tomogra-
phy (PET), and single photon emission
computed tomography (SPECT). Both
academia and industry are increasingly
employing neuroimaging tools to study
changes within the brain which occur during
disease states while using neuroimaging as
markers and outcome endpoints in clinical
trials.
This book discusses the advances, and
applications, of molecular, structural, and
functional neuroimaging techniques in Par-
kinson’s and related disorders. This book
captures the fundamental principles of neu-
roimaging techniques such with MRI, PET,
and SPECT, and attempts to review the les-
sons learnt from these neuroimaging studies
and their correspondence in the clinical
presentation of patients with Parkinson’s
disease and related disorders including
those with Lewy body dementias, atypical
parkinsonism, Huntington’s disease,
essential tremor, restless legs syndrome,
dystonia, and demyelinating syndromes.
Key features of this book include
reviewing the biomarker value of neuro-
imaging of the brain to understand disease
pathophysiology, aetiology, and progres-
sion in vivo in patients with Parkinson’s
disease and related disorders, as well as the
association between symptomatology and
molecular, structural, functional changes,
and the application of neuroimaging in
drug development and clinical trials. The
content offers a comprehensive overview
and resource for neurologists, neuroscien-
tists, neuroimagers, movement disorder
specialists, and nuclear medicine pro-
fessionals as well as students, teaching staff,
basic and clinical scientists working on
translational research, and across all levels
of industry, including proof-of-concept,
drug discovery, and clinical trials. The Edi-
tors wish to express their sincere gratitude
to all the contributing authors and hope that
readers find these articles informative,
engaging, and helpful in their practices.
Marios Politis
MD, MSc, DIC, PhD, FRCP, FEAN
Neurodegeneration Imaging Group and
Mireille Gillings Neuroimaging Centre,
University of Exeter, London,
United Kingdom
xiii
	Preface